Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes.
about
How to predict clinical relapse in inflammatory bowel disease patientsHost-microbiome interaction in Crohn's disease: A familiar or familial issue?G-CSF and GM-CSF in NeutropeniaThe Role of Laboratory Tests in Crohn's DiseaseAutoimmunity in 2015.Evolution, immunity and the emergence of brain superautoantigensLoss and Gain of Tolerance to Pancreatic Glycoprotein 2 in Celiac Disease.Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.GM-CSF and the role of myeloid regulatory cells in the pathogenesis and treatment of Crohn's disease.Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient.Identification of Antibody Against SNRPB, Small Nuclear Ribonucleoprotein-Associated Proteins B and B', as an Autoantibody Marker in Crohn's Disease using an Immunoproteomics Approach.Lessons to be learned from serum biomarkers in psoriasis and IBD - the potential role in SpA.Autoantibodies Against Glycoprotein 2 Isoforms in Pediatric Patients with Inflammatory Bowel Disease.Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy.Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1].An update on diagnostic and prognostic biomarkers in inflammatory bowel disease.Emerging concepts in non-invasive monitoring of Crohn's disease.
P2860
Q26774575-4968B81F-228B-453B-9EA7-330818BC4BBFQ26776158-63999AF3-E2A8-415D-9A77-9842C804376DQ26800954-BADD53F4-29C2-4CEB-9743-EC5118D5336EQ28075045-BA87D610-3B5E-4C02-B2B5-CE61DF31E2D5Q30248983-7DCBCF90-831A-4E47-8CDE-039EC09F57CFQ33642424-75F4E3C8-320B-4EB2-BE68-E9C79BCBD271Q35654500-AAA5D2F3-5BEA-4BED-82D5-24DED9FEACC1Q35933419-C311EB15-A8F8-47DF-8DB7-800615C0D949Q36339061-EFA20DE6-6D24-49A5-AAC7-C06AB0062F0EQ38492052-D00BBFC8-D097-49F7-8E43-EE005CE0EE6CQ38702824-E55F79F3-48B8-4CAD-9B08-6C07C7435AA0Q38756873-74EE7CAE-39B3-4672-8559-8746A8FA7534Q38972679-AF82E474-54C7-41D4-915D-9ECFC79BE5C2Q40141872-98D86E70-8846-4BEB-810B-586D9D796DA0Q40578397-604B2280-44F4-45D9-818F-FCA7F2A2734CQ40945601-B69AF6C8-91EC-4DD3-A723-DB27BCA7E1F6Q53128510-2BF45B90-3F1C-459B-A174-71C27A88AE5EQ55364545-1AD94ABE-4A30-4490-8D5E-A936C51BFDFA
P2860
Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Systematic review: new serolog ...... ction of IBD patient outcomes.
@en
type
label
Systematic review: new serolog ...... ction of IBD patient outcomes.
@en
prefLabel
Systematic review: new serolog ...... ction of IBD patient outcomes.
@en
P2093
P1433
P1476
Systematic review: new serolog ...... iction of IBD patient outcomes
@en
P2093
C Dumestre-Perard
M Rinaudo-Gaujous
P304
P356
10.1016/J.AUTREV.2014.11.004
P577
2014-11-13T00:00:00Z